在绿茶成分可能有助于减少前列腺癌高风险男性，Moffitt癌症中心的研究人员说

坦帕，佛罗里达州前列腺癌是男性癌症的第二个最常见的类型，预计在美国的220000例患者中有2015例。近年来，重点放在预防–剂防止前列腺癌的发展或进展的使用。带领的团队研究竹柏B.库马尔博士，是f.a.d.a. Moffitt癌症中心最近公布的一项随机试验评估了绿茶中的活性成分的安全性和有效性，防止人有癌前病变的前列腺癌发展的结果。这个结果将在2015美国临床肿瘤学会（ASCO）年会在芝加哥。

百分之二十的绿茶在亚洲国家食用，其中前列腺癌的死亡率是世界上最低的，而在亚洲的男性中，他们放弃原来的饮食习惯后，会增加患上前列腺癌的风险

实验室研究表明，绿茶中的儿茶酸称为物质，抑制癌细胞生长、运动和侵袭，促进肿瘤细胞的死亡。 绿茶儿茶素也防止和减少在动物模型中肿瘤的生长。表没食子儿茶素（EGCG）是最丰富的和强大的儿茶素绿茶负责这些癌症的预防作用。 

这个goal of this trial was to evaluate if a one-year intervention with green tea catechins could suppress prostate cancer development in men who had high-grade intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP).  这个researchers used decaffeinated green tea capsules called Polyphenon E that contained a mixture of catechins that predominantly contained EGCG at a dose of 200 mgs twice a day.   

这个researchers compared Polyphenon E in 49 men to placebo tablets in 48 men over a 1 year treatment period.  Overall, the difference in the number of prostate cancer cases at the end of 1 year between the two treatment groups was not statistically significant. However, in men who only had HGPIN at the beginning of the trial, they observed a lower combined rate of ASAP and prostate cancer development with Polyophenon E.  ASAP is an entity that reflects a broad group of lesions in the prostate with insufficient changes in the cells to be definitively diagnosed as prostate cancer.  Additionally, men on Polyphenon E had a significant decrease in prostate-specific antigen (PSA) levels. PSA is a biomarker that in combination with other risk factors is used to screen patients for prostate cancer, and high levels signify a higher risk of prostate cancer.

这个Moffitt researchers observed a significant increase in the levels of EGCG in the blood plasma of men on Polyphenon E, and the capsules at this dose were tolerated in this group of men.

这个ASCO poster session will take place Monday, June 1, 1:15-4:45 p.m. in S Hall A. 这个study was published in the April 14 issue of the journal Cancer Prevention Research.  Funding support was received from the National Institutes of Health/National Cancer Institute (R01 CA12060-01A1).

（注：转载时请注明复诊网）